Clinical Trials Logo

Clinical Trial Summary

This is a clinical study of CD19 / CD20 CAR-T cell infusion in the treatment of relapsed or refractory hematological malignancies in CD19 / CD20 positive B cell lines. The aim of this study was to evaluate the efficacy and safety of autologous chimeric antigen receptor T cell infusion targeting CD19/CD20 in the treatment of relapsed or refractory CD19 / CD20 positive B cell line hematological malignancies.


Clinical Trial Description

CD19 and CD20 are two proteins expressed in normal B cells and various B cell-derived hematological malignancies, including non Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (all) and chronic lymphoblastic leukemia (CLL). CD19 and CD20 are restricted to the surface of B cells. They are not expressed in hematopoietic stem cells, nor in other tissue cells. They exist in all stages of B cell development and differentiation. They are not lost from the cell surface until B cells differentiate into plasma cells. Clinical studies have found that CD19 and CD20 are excellent targets for immunotherapy of B-cell malignancies.The purpose of this study was to observe the efficacy and safety of treatment for patients with relapsed or refractory CD19 / CD20 positive B cell line hematological malignancies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04700319
Study type Interventional
Source PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Contact Xingbing Wang
Phone 13856007984
Email wangxingbing@ustc.edu.cn
Status Recruiting
Phase Early Phase 1
Start date April 19, 2019
Completion date June 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05043571 - CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia Phase 1
Recruiting NCT04691713 - CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors N/A
Recruiting NCT05648019 - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Phase 2
Recruiting NCT04702841 - CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors Early Phase 1
Recruiting NCT03267173 - Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. Early Phase 1
Recruiting NCT05429905 - Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase 1/Phase 2
Recruiting NCT05017883 - TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia N/A
Recruiting NCT03198546 - GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression Phase 1
Recruiting NCT04692948 - TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia N/A
Recruiting NCT05691153 - ThisCART19A for B-NHL Relapsed After Auto-CAR T Phase 1
Recruiting NCT05679687 - ThisCART19A Bridging to alloHSCT for R/R B-ALL Phase 1
Recruiting NCT05038696 - ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. Phase 1